Buparvaquone

Buparvaquone

Systematic (IUPAC) name
2-((4-tert-butylcyclohexyl)methyl)-3-hydroxy-1,4-naphthoquinone
Clinical data
Identifiers
CAS Registry Number	88426-33-9 N
ATCvet code	QP51AX22
ChemSpider	10807457 Y
UNII	0354RT7LG4 Y
ChEMBL	CHEMBL292009 N
Chemical data
Formula	C21H26O3
Molecular mass	326.435 g/mol
SMILES CC(C)(C)C3CCC(C\C2=C(/O)C(=O)c1ccccc1C2=O)CC3
InChI InChI=1S/C21H26O3/c1-21(2,3)14-10-8-13(9-11-14)12-17-18(22)15-6-4-5-7-16(15)19(23)20(17)24/h4-7,13-14,24H,8-12H2,1-3H3  Y Key:KLLIVCPQDTYMLC-UHFFFAOYSA-N  Y
N (what is this?)  (verify)

Buparvaquone is a hydroxynaphthoquinone antiprotozoal drug related to parvaquone and atovaquone. It is a promising compound for the therapy and prophylaxis of all forms of theileriosis. Buparvaquone has been shown to have antileishmanial activity in vitro. It can be used to treat bovine East Coast fever protozoa in vitro, along with the only other substance known - Peganum harmala.

It is the only really efficient commercial therapy product in bovine theileriosis, where it has been used since the late 1980s.

Industrial production

It was first produced in Great Britain, then in Germany. Its patent expired in the mid-2000s, and was then produced in different countries, e.g. India and RAZAK labs co. of Iran

Use in bovine theileriosis

Using a single dose of 2,5 mg/kg, the recovery rate of curable cases is 90 to 98%. In tropical theileriosis, a dosage of 2.0 mg/kg has the same efficacy. Body temperature returns to normal in two to five days. Parasitemia lowers from 12% on day 0 to 5% the next day, then to 1% by day 5 and none at day 7.^[1]

References